DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
Sandhu RK, Ezekowitz J, Andersson U. et al.
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.
Eur Heart J 2016;
37 (38) 2869-2878
We do not assume any responsibility for the contents of the web pages of other providers.